Lupin Limited — Updates, 26-05-2025: Press Release

Lupin has announced a board meeting to approve the financial results for the quarter and half-year. At the American Society of Clinical Oncology meeting, Lupin presented positive Phase 1 data for LNP7457, a novel PRMT5 inhibitor for advanced solid tumors, showing good safety and pharmacokinetics with a clear Phase 2 dose. Lupin plans to advance trials in India, strengthening its oncology pipeline targeting cancers with high unmet needs.